We present a major public resource of mRNA splicing mutations validated according to multiple lines of evidence of abnormal gene expression. Likely mutations present in all tumor types reported in the Cancer Genome Atlas (TCGA) were identified based on the comparative strengths of splice sites in tumor versus normal genomes and then validated by respectively comparing counts of splice junction spanning and abundance of transcript reads in RNA-Seq data from matched tissues and tumors lacking these mutations.
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We present a major public resource of mRNA splicing mutations validated according to multiple lines of evidence of abnormal gene expression. Likely mutations present in all tumor types reported in the Cancer Genome Atlas (TCGA) were identified based on the comparative strengths of splice sites in tumor versus normal genomes and then validated by respectively comparing counts of splice junction spanning and abundance of transcript reads in RNA-Seq data from matched tissues and tumors lacking these mutations.
The comprehensive resource features 351,423 of these validated mutations, the majority of which (69.1%) are not featured in the Single Nucleotide Polymorphism Database (dbSNP 150). There are 117,951 unique mutations which weaken or abolish natural splice sites, and 244,415 mutations which strengthen cryptic splice sites (10,943 affect both simultaneously). 27,803 novel or rare flagged variants (with <1% population frequency in dbSNP) were observed in multiple tumor tissue types. Single variants or chromosome ranges can be queried using a Global Alliance for Genomics and Health (GA4GH)-compliant web Beacon, Validated Splicing Mutations, either separately or in aggregate alongside other beacons through the public Beacon Network (http://www.beacon-network.org/#/search?beacon=cytognomix), as well as through our website (https://validsplicemut.cytognomix.com/).
Introduction:
Next generation sequencing continues to reveal large numbers of novel variants whose impact cannot be interpreted from curated variant databases or through reviews of peer-reviewed biomedical literature 1 . This has created a largely, unmet need for unequivocal sources of information regarding the molecular phenotypes and potential pathology of variants of unknown significance (VUS); in cancer genomes, such sources are critically needed to assist in distinguishing driver mutations from overwhelming numbers of bystander mutations. VUS classification criteria highlight the limitations in genome interpretation due to ambiguous variant interpretation. Of the 458,899 variant submissions in NCBI's ClinVar database with clinical interpretations, nearly half (n=221,271) are VUS (as of November 5th 2018; https://www.ncbi.nlm.nih.gov/clinvar/submitters/). Only 10,784 variants in ClinVar have been documented to affect mRNA splicing at splice donor or acceptor sites, with 1,063 of these being classified as VUS, and cryptic mRNA splicing mutations are not explicitly described. The current ACMG criteria 2 for variant pathogenicity prevent clinical classification of most VUS. Functional evidence that VUS either disrupt or abolish expression of genes has been sought to improve classification and provide insight into the roles, if any, of individual VUS in predisposing or causing disease. We present a comprehensive data repository for a relatively common mutation type (cis-acting variants that alter mRNA splicing). Mutations are predicted with information theory-based analyses 3 , and supported with functional evidence that variants in tumor genomes are specifically associated with abnormally spliced mRNAs that are infrequent or absent in transciptomes lacking these variants 4 .
Information Theory (IT) has been proven to accurately predict impact of mutations on mRNA splicing, and has been used to interpret coding and non-coding mutations that alter mRNA splicing in both common and rare diseases 3,5-15 . We have described an IT-based framework for the interpretation and prioritization of non-coding variants of uncertain significance, which has been validated in multiple studies involving novel variants in patients with history or predisposition to heritable breast and/or ovarian cancer [11] [12] [13] [14] [15] .
The Cancer Genome Atlas (TCGA) Pan-Cancer Atlas (PCA) is a comprehensive integrated genomic and transcriptomic resource containing data from >10,000 tumors across 33 different tumor types 16 . Here, we utilized IT-based tools for assessment of high quality sequenced variants in TCGA patients for their potential impact on mRNA splicing. The accuracy of predicted mutations was evaluated with an algorithm we previously developed that compares transcripts from individuals carrying these variants with others lacking them. The results of these genome-wide analyses are presented using an online resource (https://validsplicemut.cytognomix.com/) which can be queried through the Beacon Network (https://beacon-network.org) 17 .
Materials & Methods:

TCGA Data Acquisition and Processing
Controlled-access data was obtained with permission from the Data Access Committee at NIH for TCGA and from the International Cancer Genomics Consortium. Patient RNA sequencing BAM files (tumor and normal, when available) and their associated VCF files (HG19) were initially obtained from the CancerGenomeHub (CGhub). Files were later downloaded through Genomic Data Commons (https://gdc.cancer.gov/) using the GDC Data Transfer Tool, as CGhub was decommissioned mid-project.
Variants in VCF files which did not pass quality control (QC) were not analyzed.
Information Analysis and RNA-Seq Validation of Splicing Variants
We used the Shannon Pipeline software (which applies IT to rapidly perform high-throughput, in silico prediction of the impacts of variants on mRNA splicing) 18 to analyze all QC-passing variants in VCFs from TCGA (>168 million variants) to evaluate their potential impact on splice site binding strength (changes in information content, Ri, measured in bits). Variants which were predicted to strengthen known natural sites or weaken cryptic splice sites were excluded from all subsequent analyses.
To validate the potential impact of Shannon Pipeline-flagged mutations, Veridical software analyzed genomic variants (including insertions and deletions) by comparing the RNA-Seq alignment in the region surrounding the variant with the corresponding interval in control transcriptomes (normal and tumor tissue of the same type) lacking the variant 4, 19 . Veridical: a) counts abnormally spliced reads in RNA-Seq data (categorized as: cryptic site use, exon skipping, or intron inclusion [containing or adjacent to the flagged mutation]), b) applies the Yeo-Johnson transformation to these results, and c) determines the null hypothesis probability (p-value) that the transformed read count corresponds to normal splicing. In tumor types where normal controls were not available, a set of RNA-Seq datasets from 100 different normal tissues from TCGA were used (e.g. a combination of 5 tissue types: BRCA, BLCA, LUAD, KIRC, PRAD).
Veridical results that were not significant for a particular variant (p-value > 0.05 for all of the splicing categories) were not further analyzed. After analysis, Veridical validated 351,423 unique mutations for their direct impact on mRNA splicing ( Table 1 ). The Shannon pipeline-flagged and Veridical-filtered results were combined into a single large table (Dataset 1), the source data for the ValidSpliceMut SQL database and the associated Beacon application.
Development of the ValidSpliceMut database and Beacon
We created a publicly accessible Application Programming Interface (API) (https://beacon.cytognomix.com) that can be utilized to programmatically query variants passing filter To generate IGV images presented on the webpage, a bash script was written to automatically load the RNA-Seq BAM file of a patient with a mutation of interest into IGV, set the viewing window within the region of interest (300nt window, centered on the variant), sorted to bring reads containing the variant of interest to the top of the screen (to increase chance of visualizing mutant splice form), followed by a screen capture. The generation and storage of IGV images for all patient-mutation pairs would be prohibitive due to limitations in time and server space requirements. Therefore IGV images showing evidence of splicing abnormalities were generated only for patient-mutation pairs which met the most stringent criteria: the mutation was required to be flagged for junction-spanning cryptic site use, exon skipping, or intron inclusion (with mutation); the flagged category must include 5 or more reads in this category; if the variant is present in the dbSNP database (release 150), the frequency was required to be < 1% of the population; and the Veridical results, in which the mutations flagged were required to exhibit p ≤ 0.01 for at least one form of evidence of a splicing abnormality. In some cases, the splicing event observed by Veridical may not be present within the image window as the automated procedure used to create these images does not present all evidential sequence reads due to limitations on the number of reads that are shown. Additionally, reads appearing as exon skipping may instead indicate a pre-existing cryptic site outside of the viewing window (see Table 2 ; FAT1:g.187521515C>A [c.11641-1G>T] and SMAD3:g.67482748C>G [c.1155-3C>G]).
Results and Discussion:
We have derived a GA4GH-standardized, searchable web resource for a large set of validated mRNA splicing variants present in diverse tumor types. All variants passing QC in TCGA cancer patients were analyzed with the Shannon pipeline 18 . This revealed that 1,297,242 variants were predicted to have significant impacts on normal mRNA splicing (347,549 natural and 985,112 cryptic splice sites; 35,419 affecting both types). Subsequent RNA-Seq analysis with Veridical 4 provided evidence of abnormal gene expression specifically associated with a subset of these variant(s), identifying 351,423 unique mutations.
Results are searchable through either the Beacon Network (https://beacon-network.org), or our publiclyaccessible webpage (https://validsplicemut.cytognomix.com/).
Our results contrast with another TCGA study that investigated alternative mRNA splicing 21 and demonstrated a limited set of non-constitutive exon-exon junctions attributable to cis-acting splicing mutations (n = 32). The 2,736 novel or rare variants that we report which specifically activate cryptic splicing (significant 'junction-spanning cryptic site use' reads found by Veridical), exceed the number reported in another study that analyzed all available TCGA tumor transcriptomes (n=1,964) 22 .
Validated variants were also tallied by tumor tissue type in our study ( Table 1) . 33.6% of unique mutations (n=117,951) significantly weaken natural splice sites, while 69.6% (n=244,415) strengthen novel or pre-existing cryptic sites. 242,983 variants (69% of all flagged variants) are absent from dbSNP150. 73,975 variants (21%) are found in <1% of the population. Valid mutations lacking rsIDs represent either novel or recently observed variants. This low level of dbSNP saturation is consistent with the idea that many currently unknown mRNA splicing mutations may yet be discovered through additional sequencing studies.
In Table 2 , we highlight a subset of validated splicing mutations (n=25) which were identified in known driver genes implicated in the COSMIC (Catalogue Of Somatic Mutations In Cancer; https://cancer.sanger.ac.uk/cosmic) Cancer Gene Census catalog (CGC) 23 . These mutations are associated with either increased exon skipping, intron inclusion, and/or cryptic site use. Mutations in Table 2 The combined splicing impact of these variants is significant exon skipping, intron inclusion, and use of the activated cryptic site.
Because of the requirement for expression validation, this resource presents a set of splicing abnormalities in which we have the highest confidence. We anticipate that some correct predictions of the Shannon pipeline may have not been validated by Veridical due to the limitations of mRNA detection; for example, either low expression of the gene harboring the mutation or nonsense-mediated decay of the corresponding transcript could be consistent with the effects of a valid splicing mutation, but in the absence of a sufficient number of abnormal reads, the mutation could not be confirmed. Furthermore, at the time that the current analysis was performed, the available Shannon pipeline version did not report regulatory splicing variants adjacent to constitutive and cryptic splice sites which influence exon definition. Due to the substantial processing required for the complete TCGA dataset, the present analysis does not incorporate the effects of these variants on exon definition, which we have modeled by IT 6 ; it does not predict the relative abundance of leaky, natural and cryptic isoforms, though such information might be inferred from the expression data on each tumor. The current version of Shannon pipeline does integrate predictions of splicing regulatory sequences and accounts for relative abundance of mRNA isoforms by exon definition, and is available through the MutationForecaster system (https://mutationforecaster.com).
The Validated Splicing Mutation resource should substantially contribute to reducing the number of outstanding VUS in tumor (and possibly some germline) genomes, and substantially increases the number of splicing-related variants based on previously unappreciated molecular consequences, in particular, activation of cryptic splice sites. In our previous study 19 , a subset of the TCGA breast cancer patient data was evaluated with IT-based tools, identifying 988 variants as significantly altering normal splicing by Veridical (19% of total mutations flagged by IT). This database greatly expands the size of the repository. Here, a higher ratio of rare or novel mutations have been validated by Veridical (24% of total mutations were flagged by IT). The higher yield found could be related to the same mutation being present in multiple samples from the same tumor type and other tumor tissues, which would be expected to increase the probability of observing abnormally expressed splice forms for the mutation.
Data Availability:
Zenodo: Dataset 1. Validated natural and cryptic mRNA splicing mutations. Source data computed by
